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Research Note: Prognostic model research: overﬁtting, validation and applicationIntroduction
In physiotherapy, many prognostic models have been developed
to predict future outcomes after musculoskeletal conditions,
including neck pain.1 Prognostic models combine several character-
istics to predict the risk of an outcome for individual patients and
may enable personalised prevention and care. In practice, they can be
used to inform patients and relatives on prognosis, and to support
clinical decision-making. Moreover, models may be useful to stratify
patients for clinical trials. Prediction models are increasingly being
published, including 99 prognostic models for neck pain alone, pre-
dicting recovery (pain reduction, reduced disability, and perceived
recovery).2 Although guidelines for developing and reporting prog-
nostic models have been proposed,3,4 a recently proposed assessment
tool found that many prognostic models in physiotherapy are prone
to risks of bias.2,5
Various limitations have been noted regarding design and ana-
lyses, which make models at risk of overﬁtting.2 Overﬁtting relates to
the notion of asking too much from the available data, which results
in overly optimistic estimates of model predictive performance; re-
sults that cannot be validated in underlying or related populations.6
Consequently, the model may predict poorly, with serious limita-
tions when the model is applied in clinical practice: it does not
separate low-risk from high-risk patients (poor discrimination), and
may give unreliable or even misleading risk estimates (poor
calibration).
We aim to describe a number of challenges related to the design
and analysis in different stages of prognostic model research, and
opportunities to reduce overﬁtting (summarised in Table 1). We
emphasise validation before the application of prediction models is
considered in clinical practice. For illustration, we consider the Öre-
bro Musculoskeletal Pain Screening Questionnaire (OMPQ) (Table 2).7
The model has extensively been validated, and its use is recom-
mended by clinical guidelines.8 We also consider the Schellingerhout
non-speciﬁc neck pain model predicting recovery after six months
(Table 2),9 which was indicated as one of the few externally validated
models with a low risk of bias.2
Model development
The development of a prognostic model involves a number of
steps. These include handling of missing data, selection and coding of
predictor variables, choosing between alternative statistical models,
and estimating model parameters.10 Prognostic models are usually
developed with multivariable regression techniques on data from
(prospective) cohort studies, while machine learning techniques are
gaining increased attention.
Missing data is common in prognostic research. A complete case
analysis is often conducted (ie, the exclusion of participants that have
missing data on one or multiple predictor variables, resulting in
smaller sample size). As a consequence, the number of events per
variable may drop below the number deemed necessary for reliablehttps://doi.org/10.1016/j.jphys.2019.08.009
1836-9553/© 2019 Australian Physiotherapy Association. Published by Elsevier B.V. This is
licenses/by-nc-nd/4.0/).modelling (Table 1), increasing the risk of overﬁtting. Better ap-
proaches are imputation methods,10 where missing values may be
substituted with the mean or the mode with single imputation, andm
completed data sets are created with multiple imputation procedures.
Multiple imputation is recommended, because single imputation ig-
nores potential correlation of predictors and leads to an underesti-
mation of variability of predictor values among subjects.11 This may
lead to an overestimation of the precision of regression coefﬁcients.
Imputation methods are widely available through modern statistical
software.
It is difﬁcult to select the most promising predictors. Selection of
candidate predictors based on literature and expert knowledge is
often preferred over selection based on a relatively limited dataset.10
Also, some related predictors can sometimes be combined in simple
scores. For example, comorbid conditions are often combined in a
comorbidity score,12 and frailty in the elderly can be scored according
to various characteristics.13 After selection of candidate predictors,
the set of predictors may be reduced; this can be done using uni-
variate analysis and/or stepwise methods. However, both approaches
do not truly reduce the problem of statistical overﬁtting, since the
model speciﬁcation is driven by ﬁndings in the data. Univariate
analysis is common as a ﬁrst step to select the most potent risk fac-
tors, which are then used in multivariable analysis. This approach was
followed in the development of the OMPQ (Table 2). A common
alternative is to use backward stepwise selection from a model that
includes all candidate predictors, as was done by Schellingerhout to
develop a model to predict non-speciﬁc neck pain (Table 2). Stepwise
selection procedures are known to result in biased regression coef-
ﬁcient estimates (testimation bias).6 A modern approach to reduce
such testimation bias and overﬁtting is by shrinkage of regression
coefﬁcients towards zero.10 A key example of this approach is the
Least Absolute Shrinkage and Selection Operator, which penalises for
the absolute values of the regression coefﬁcients. It shrinks some
coefﬁcients to zero, which means that predictors are dropped from
the model.
Validation: apparent, internal and external performance
The aim of prognostic models is to provide accurate risk pre-
dictions for new patients. Therefore, validation of prognostic models
is crucial. Three types of validation can be distinguished: apparent,
internal and external validation.
Apparent validation entails the assessment of model performance
directly in the derivation cohort. Because the regression coefﬁcients
are optimised for the derivation cohort, this provides optimistic es-
timates of the model’s performance (overﬁtting). To correct for
overﬁtting, several internal validation procedures are available.
Bootstrap resampling and cross-validation provide stable estimates
with low bias and are therefore recommended.10
Before a prognostic model can be applied in practice it is crucial
to explore how the model performs outside the setting in which it
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Table 1
Overview of challenges and opportunities categorised by the stage of prognostic model research in which they occur, and illustrated with two prediction models.7,9
Stage of
prognostic
model research
Challenges Opportunities Örebro
Musculoskeletal
Pain Screening
Questionnaire
Schellingerhout
non-speciﬁc
neck pain model
Design Insufﬁcient sample size Collaborative efforts to reach
. 10 EPV, cross-validate
across setting
No information on EPV Restricted to 17 predictors
based on EPV (10)
Development Inappropriate handling
of missing data;
complete case analysis
Multiple imputation methods Complete case analysis Multiple imputation with
5 repetitions
Development Selection of predictors
based on univariate
analysis or stepwise
selection procedures
Shrinkage and penalisation in
multivariable
analysis
Univariate analysis Backward stepwise selection
Internal
validation
Apparent validation or
inefﬁcient internal
validation procedures
Bootstrap resampling or
cross-validation
Apparent validation Apparent validation
External
validation
Full model equation is
not presented
Present full model equation Yes Yes
External
validation
No external validation Validation of models in cohort
other than development cohort
through collaborative
research
Externally validated; AUC,
but no calibration plot
Externally validated; AUC and
calibration plot
EPV = events per variable; AUC = area under the receiver operating characteristic curve.
2 Appraisal Research Notevalidity relates to the generalisability of the prognostic model to
another population.10 A cross-validation across different non-
random parts of the development data gives an indication of
external validity.14 Heterogeneity in predictor effects across set-
tings indicates that the model should be calibrated to each speciﬁc
setting, to achieve robust model performance across settings. To
enable external validation of the model the full model equation
should be presented in the paper (Table 1). The OMPQ has been
extensively validated in international cohorts,15 while such
external validation is rare for other prognostic models for muscu-
loskeletal conditions.2,16Performance measures
Model performance at internal and external validation is
commonly expressed with discrimination and calibration. Discrimi-
nation indicates the ability of the model to differentiate betweenTable 2
Overview of prognostic model characteristics of the Örebro Musculoskeletal Pain Screenin
Örebro Musculoskeletal
Pain Screening
Questionnaire
Development
Patient population
of development
cohort
n = 137; adult patients; acute/subacute back pai
Outcome Accumulated sick leave; 6 months follow-up
Predictors 21 predictors: physical functioning, fear-avoidan
the experience of pain, work, and reactions to th
External validation
External validation n = 106; adult patients; acute/subacute low back
workers’ compensation and medical practitioner
observational study; Australia17
Model performance AUC 0.80 (CI 95% 0.66 to 0.93); no calibration pl
Application
Practical application Recommended in clinical guidelines as screening
and used to select trial participants19high-risk and low-risk patients. It can be measured by the concor-
dance statistic (C-statistic or area under the receiver operating
characteristic curve: AUC). The AUC ranges between 0.50 (no
discrimination) and 1.00 (perfect discrimination). For instance, the
OMPQ was validated in an observational study of patients with acute
back pain in Australia.17 At external validation of the OMPQ the AUC
was 0.80 (95% CI 0.66 to 0.93) for absenteeism at 6 months (Table 2).17
The discriminative ability of the Schellingerhout non-speciﬁc neck
pain model was lower: AUC 0.66 (95% CI 0.61 to 0.71) at development,
and validation cohort AUC 0.65 (95% CI 0.59 to 0.71).9
Calibration refers to the agreement between predicted and
observed probabilities. This agreement can be illustrated with a
calibration graph. Ideally, the plot shows a 45-deg line with calibra-
tion slope 1 and intercept 0. Calibration is more informative at
external than internal validation because a model is expected to
provide correct predictions for the derivation cohort it is ﬁtted on. At
external validation, the Schellingerhout non-speciﬁc neck pain
score chart showed reasonable calibration (Figure 1); it slightlyg Questionnaire and the Schellingerhout non-speciﬁc neck pain model.
Schellingerhout non-speciﬁc
neck pain model
n; Sweden7 n = 468; adult patients (18 to 70 yrs);
non-speciﬁc neck pain; primary care;
The Netherlands9
Global perceived recovery; dichotomised into
‘recovered or much improved’ versus ‘persistent
complaints’; 6 months follow-up
ce beliefs,
e pain
9 predictors: age, pain intensity, previous neck
complaints, radiation of pain, accompanying low
back pain, accompanying headache, employment
status, health status, and cause of complaints
pain;
referral;
n = 346; adult patients (18 to 70 yrs);
non-speciﬁc neck pain; primary care; randomised
controlled trial; PANTHER trail; United Kingdom9
ot AUC 0.65 (CI 95% 0.59 to 0.71); calibration plot
instrument,8 Score chart9
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Figure 1. Calibration of the Schellingerhout non-speciﬁc neck pain score chart in
external validation cohort.
 = deciles of risk
—— = Perfect calibration
Adapted from Schellingerhout et al.9
Appraisal Research Note 3overestimated the risk of persistent complaints in adult patients
presenting with non-speciﬁc neck pain.9 More severe miscalibration
is common for prediction models.18
Application of prognostic models in practice
A prognostic model is more likely to be applicable for imple-
mentation in practice if the model was developed with high-quality
data from an appropriate study design, and with careful statistical
analysis.10 Even better is when the model is externally validated in the
setting where it is to be used.14 For instance, the OMPQ is recom-
mended in clinical guidelines to be applied in screening to predict
delayed recovery,8 and was used to select trial participants,19 likely
motivated by the extensive and positive external validation studies
across multiple settings. When a prognostic model is deemed appro-
priate for implementation, the impact (clinical effectiveness and costs)
of the use of the model in clinical practice should be studied.4 Although
recommended, these clinical impact studies are scarce, and some
prediction models have been recommended to be used in clinical
practice without adequate evaluation of their (cost-)effectiveness.
The presentation of clinical prediction models is important to
facilitate implementation of prognostic models in practice. The Schel-
lingerhout model was presented as a score chart that can readily be
used by physicians. Although the score chart may be easy to use, pre-
dictions of risks are only approximate because continuous predictors
are categorised and regression coefﬁcients are rounded. The score chart
should ideally be externally validated across various settings before it
can be considered for use in broader practice. Other common formats
include web-based calculators and apps for mobile devices.10,20Summary
The aim of prognostic models for predicting future outcomes after
musculoskeletal conditions is to provide accurate and patient-speciﬁc
estimates of the risk of relevant clinical outcomes such as delayed
recovery. These models may be applied in primary care to identify
patients likely to have poor outcomes. Most models in physiotherapy
have been judged to be at moderate to high risk of bias.2 Approaches
to reduce overﬁtting should be better utilised. These include appro-
priate handling of missing data, careful selection of predictors with
domain knowledge, and internal and external validation (Table 1).
Assessment of performance across a range of settings may show
suboptimal results, speciﬁcally with respect to calibration of pre-
dictions. Such suboptimal performance may motivate updating of a
model before it can be considered for application in a speciﬁc
setting.10 Furthermore, clinical impact studies are recommended to
assess the (cost-) effectiveness of a prognostic model in clinical
practice. The presentation format of a prognostic model is also
important, as this can facilitate implementation of prognostic models
in clinical practice to improve decision-making and outcome by
personalised medicine.
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